The carotid bodies are sensitive to glucose in vitro and can be stimulated to cause hyperglycemia in vivo. The aim of this study was to determine if the carotid bodies are involved in basal glucoregulation or the counterregulatory response to an insulin-induced decrement in arterial glucose in vivo. Dogs were surgically prepared >16 days before the experiment. The carotid bodies and their associated nerves were removed (carotid body resected [CBR]) or left intact (Sham), and infusion and sampling catheters were implanted. Removal of carotid bodies was verified by the absence of a ventilatory response to NaCN. Experiments were performed in 18-h fasted conscious dogs and consisted of a tracer ([3- 3 H]glucose) equilibration period (-120 to -40 min), a basal period (-40 to 0 min), and an insulin infusion (1 mU · kg -1 · min -1 ) period (0-150 min) during which glucose was infused as needed to clamp at mildly hypoglycemic (65 mg/dl) or euglycemic (105 mg/dl) levels. Basal (8 µU/ml) and clamp (40 µU/ml) insulin levels were similar in both groups. Basal arterial glucagon was reduced in CBR compared with Sham (30 ± 2 vs. 40 ± 2 pg/ml) and remained reduced in CBR during hypoglycemia (peak levels of 36 ± 3 vs. 52 ± 7 pg/ml). Cortisol levels were not significantly different between the 2 groups in the basal state, but were reduced during the hypoglycemic clamp in CBR. Catecholamine levels were not significantly different between the 2 groups in the basal and hypoglycemic periods. The glucose infusion rate required to clamp glucose at 65 mg/dl was 2.5-fold greater in CBR compared with Sham T here is considerable uncertainty as to the site at which decrements in blood glucose are sensed. Sites in the brain (1), portal vein (2,3), liver (4), and pancreas (5) are all sensitive to blood glucose. Despite intensive investigation, however, the physiological role of these glucose-sensitive regions are highly controversial because no one site can completely explain the full counterregulatory response to hypoglycemia.
Evidence That Carotid Bodies Play an Important Role in Glucoregulation In
T here is considerable uncertainty as to the site at which decrements in blood glucose are sensed. Sites in the brain (1), portal vein (2,3), liver (4) , and pancreas (5) are all sensitive to blood glucose. Despite intensive investigation, however, the physiological role of these glucose-sensitive regions are highly controversial because no one site can completely explain the full counterregulatory response to hypoglycemia.
We tested the hypothesis that the carotid bodies (or receptors near this site) are instrumental in detecting a decrement in blood glucose. This hypothesis was based on evidence that 1) the carotid bodies can detect glucose (6) (7) (8) , 2) the carotid bodies have the "circuitry" to provide input to centers involved in glucoregulation (7) (8) (9) (10) , and 3) the carotid bodies have unique physiological characteristics making them potentially highly sensitive to changes in blood glucose content (high blood flow and metabolic rate per gram tissue) (11) .
To examine the role of the carotid bodies (or receptors anatomically near them), carotid body resected (CBR) conscious dogs or dogs having undergone a sham surgery (Sham) were studied in the basal state and during hyperinsulinemic, euglycemic, or hypoglycemic clamps. Isotope dilution methods were used to calculate glucose kinetics.
Y. KOYAMA AND ASSOCIATES
portal vein and hepatic artery were accessed from the abdominal incision, dissected free of surrounding tissue, and fitted with 6.0-and 3.0-mm (ID) flow probe cuffs, which were then secured around the vessels. Catheters and the Doppler probe lead were stored under the skin at the site where access to vessels was achieved.
An 8-cm ventral midline incision was made 1 cm proximal to the mylohyoideus muscle and extended 8 cm distally. Blunt dissection was used to expose the left and right common carotid arteries at the point of their bifurcation into the external and internal branches. The tissue at the carotid sinus in which the carotid bodies were thought to lie was identified and excised. After surgical access to the carotid sinus areas, the vagosympathetic trunk, cervical and distal ganglion, hypoglossal nerve, and glossopharyngeal nerve were identified. Extreme care was taken in the dissection not to disrupt or damage these structures. However, because the carotid bodies are difficult to visualize, associated nerves supplying the skeletonized area were transected to insure that if carotid body tissue remained, it would not be able to transmit signals to the brain. Segments (1 cm) of the common carotid and each branch were skeletonized and cleared of all tissue. Care was taken not to disrupt the occipital, cranial, laryngeal, or other arterial branches in close proximity. To assure disruption of all neural tissue, the skeletonized areas were swabbed with alcohol (13) . After the closure of the incision sites, the effectiveness of carotid body removal was verified by the absence of a ventilatory response to NaCN (20-40 µg/kg). Postoperative assessments were performed after the surgical recovery of the animals, with close attention paid to any clinical signs of impaired nerve function. These assessments included assessment of heart rate, ability to consume food, salivate, and masticate and observations for any gastrointestinal abnormalities. None of the animals used in the experiments exhibited any complications or impairments in normal function.
Only animals that had a leukocyte count <18,000/mm 3 , a hematocrit >36%, normal stools, and a good appetite (consuming all of the daily ration) were used for experiments. Studies were conducted after an 18-h fast because dogs are postabsorptive after this interval. On the day of the experiment, the subcutaneous ends of the catheters were freed from subcutaneous pockets through small skin incisions made under local anesthesia (2% lidocaine; Astra Pharmaceutical Products, Worcester, MA). The contents of each catheter were aspirated, and the catheters were flushed with saline. Silastic tubing was connected to the exposed catheters. Saline was infused in the arterial catheter throughout the experiments (0.1 ml/min). ) was started. Arterial glucose was clamped at moderately hypoglycemic (CBR, n = 6; Sham, n = 6) or euglycemic (CBR, n = 5; Sham, n = 6) levels. Exogenous glucose was varied based on feedback from rapid arterial sampling (<5 min) for the purpose of clamping glucose. H]glucose was added to the glucose infusate at a specific activity of ~10,000 dpm/mg. This procedure minimizes changes in arterial specific activity and, by doing so, also minimizes modeling errors in the calculation of glucose kinetics. Arterial samples were also drawn at 10-min intervals from -40 to 150 min. Portal and hepatic vein samples were drawn at -40, -20, 0, 10, 30, 50, 60, 80, 100, 110, 130, and 150 min. Hepatic artery and portal vein blood flow were recorded continuously from the frequency shifts of the pulsed sound signal emitted from the blood flow probes (12) . Heart rate and blood pressure were monitored throughout all studies. Arterial blood gases were determined at -30, 50, and 120 min. Processing of blood samples. Plasma glucose levels were determined during experiments by the glucose oxidase method using a Beckman Glucose Analyzer 2 (Beckman Instruments, Fullerton, CA). For the determination of plasma [ 3 H]glucose radioactivity, samples were deproteinized with barium hydroxide (Sigma, St. Louis, MO) and zinc sulfate (Sigma) on the day of the study. Samples were centrifuged, and the supernatant was evaporated and reconstituted in 1 ml water and 10 ml Ecolite+ (ICN, Irvine, CA). Radioactivity was then determined by liquid scintillation counting using a Beckman LS-5000TD (Beckman Instruments). ICG concentration was measured spectrophotometrically (805 nm) in arterial and hepatic vein plasma immediately after experiments. Plasma nonesterified fatty acids were measured spectrophotometrically using the kit made by Wako Chemicals (Richmond, VA). Whole blood lactate, alanine, and glycerol concentrations were determined in samples deproteinized with a 1:3 volume of 4% perchloric acid by enzymatic methods (14) on a Monarch 2000 centrifugal analyzer (Instrumentation Laboratories, Lexington, MA). Acid-based analyzer ABL30 (Radiometer, Copenhagen) was used for determination of arterial blood gases and pH. Corrections were made between the temperature setting of the analyzer and the body temperature of the dogs.
Immunoreactive insulin was measured using a double antibody system (interassay coefficient of variation [CV] of 10%). Immunoreactive glucagon was measured in plasma samples containing 50 µl of 500 kallikrein inhibitor units/ml Trasylol (Bayer, Kankakee, IL) using a double antibody system (interassay CV 7%) modified from the method developed for insulin. Plasma norepinephrine and epinephrine levels were determined using a high-performance liquid chromatography technique (interassay CVs 11 and 13%, respectively). Plasma cortisol was measured using the Coat-A-Count Cortisol Radioimmunoassay Kit (Diagnostic Products, Los Angels, CA; interassay CV 6%). The methods used for hormone analyses by this laboratory have been described previously (15) . Calculations. Total glucose appearance (R a ) and glucose disappearance (R d ) were determined using the 2-compartment model described by Mari (16) for non-steady state with [3- 3 H]glucose as the tracer. The calculations were adapted to account for variable isotope infusion in the clamp period. Endogenous R a was calculated as the total R a minus the exogenous glucose infusion rate. The 2-compartment approach does not result in the underestimation of R a values seen under hyperinsulinemic conditions using the modified 1-compartment model (16) .
Net hepatic substrate balance was determined by the formula HAF ϫ ([A] -[H]) + PVF ϫ ([P] -[H]), where [A], [P], and [H]
are the arterial, portal vein, and hepatic vein substrate concentrations, and HAF and PVF are the hepatic artery and portal vein blood (or plasma) flows, respectively. In the calculations of lactate and glucose, the sign (+/-) was reversed so that net output would be a positive number. Doppler-determined blood flows were used to calculate balances, except in cases where probes did not elicit a clear electrical signal. In these instances, the ICG extraction method was used to determine total hepatic flow (17) with the assumption that 80% of the flow was via the portal vein.
Statistics were performed using StatView and SuperANOVA (Abacus Concepts, Berkeley, CA) on a Macintosh computer. Statistical comparisons between groups and over time were made using analysis of variance (ANOVA) designed to account for repeated measures. Specific time points were examined for significance using contrasts solved by univariate repeated measures. Statistics are reported in the corresponding table or figure legend for each variable. Differences were considered significant when P values were ≤0.05 unless specified otherwise. Data are expressed as means ± SE.
RESULTS
Basal characteristics. Table 1 shows the arterial blood gas samples, blood pressure, heart rate, and plasma hormones during the basal period. Data were compiled by pooling the basal period of hypoglycemic and euglycemic clamp studies. Although pH was similar in both groups, pCO 2 were significantly higher, and PO 2 was significantly lower in CBR. Arterial plasma glucagon was significantly lower in CBR. Arterial plasma catecholamine and cortisol levels were not significantly different in the 2 groups. Hypoglycemic clamp studies Arterial plasma insulin, arterial glucose, and glucose infusion rates. Arterial plasma insulin rose from a basal value of 8 ± 1 to 40 ± 2 µU/ml in Sham and 8 ± 1 and 41 ± 2 µU/ml in CBR during the test period in hypoglycemic studies (Fig. 2) . The rate of decline and steady-state arterial glucose concentrations were clamped at equivalent values (steady concentrations of 65 ± 1 mg/dl in CBR and 65 ± 1 mg/dl in Sham) (Fig. 2) . During the hypoglycemic clamps, the glucose infusion rate required to clamp arterial glucose was 2. , last 30 min of the clamp). Net hepatic glucose output was 1.8 ± 0.2 mg · kg -1 · min -1 in the basal state in Sham and 1.7 ± 0.4, 1.6 ± 0.2, and 1.4 ± 0.2 mg · kg -1 · min -1 at intervals of 10-50, 60-100, and 110-150 min, respectively. Basal net hepatic glucose output (NHGO) was 1.3 ± 0.2 mg · kg -1 · min -1 in CBR, and rates were 1.1 ± 0.2, 1.3 ± 0.2, and 1.1 ± 0.2 mg · kg -1 · min -1 at intervals of 10-50, 60-100, and 110-150 min, respectively. Although NHGO tended to be reduced in CBR compared with Sham, differences were not significant. Arterial plasma glucagon, catecholamine, and cortisol response. Figure 5 shows arterial plasma glucagon and cortisol during hypoglycemic clamp studies. Arterial glucagon increased significantly during the hypoglycemic clamp in Sham but not CBR. Cortisol levels were significantly reduced in CBR compared with Sham by ANOVA at the P = 0.055 level during the hypoglycemic period. Figure 6 shows arterial plasma norepinephrine and epinephrine concentrations during hyperinsulinemic, hypoglycemic clamp studies. The catecholamine concentrations were not significantly different between CBR and Sham. Arterial concentrations and net hepatic balances of alanine, glycerol, lactate, and free fatty acids. Table 2 shows that there were no significant differences in arterial concentrations or net hepatic balances of alanine, lactate, and free fatty acids in the basal state or during the hypoglycemic clamp. Blood glycerol levels in CBR were similar to Sham in the basal state, but the response to hypoglycemia in CBR was attenuated at the last sampling interval. Nevertheless, net hepatic glycerol uptake was similar in the basal state and throughout the hypoglycemic clamp in the 2 groups. Total hepatic blood flow. Total hepatic blood flow was 30 ± 4 ml · kg -1 · min -1 in the basal state in Sham and 30 ± 4, 31 ± 3, and 31 ± 3 ml · kg -1 · min -1 at intervals of 10-50, 60-100, and 110-150 min, respectively. Basal total hepatic blood flow was 27 ± 1 in CBR, and rates were 26 ± 2, 29 ± 3, and 30 ± 2 ml · kg -1 · min -1 at intervals of 10-50, 60-100, and 110-150 min, respectively. There were no significant differences between groups. Euglycemic clamp studies. Table 3 shows the result of euglycemic clamp studies in Sham and CBR. Arterial Data are means ± SE. n = 12 and 11 in Sham and CBR, respectively. *Significant difference from Sham (P < 0.05).
plasma glucose and insulin were similar throughout the study period in both groups. Basal plasma glucagon was significantly lower in CBR, and levels remained lower for the first 2 sampling intervals of the clamp. Cortisol was not significantly different between the 2 groups except at the first sampling interval during the euglycemic clamp, at which time levels were higher in Sham. This result seems to be an atypical response of Sham rather then a cortisollowering effect of carotid body resection because a large body of data, including our own, using the same experimental design indicate that cortisol is normally unchanged during a euglycemic clamp (18) . There were no detectable effects of carotid body resection on catecholamine levels during euglycemic clamps. NHGO and R a were not significantly different between groups. R d , however, was increased by ~3 ml · kg -1 · min -1 , resulting in an elevated exogenous glucose infusion rate in CBR compared with Sham. Portal vein and hepatic artery blood flows were similar during euglycemic clamps in Sham and CBR (data not shown).
DISCUSSION
These studies were designed to test the novel hypothesis that the carotid bodies or receptors anatomically nearby play a glucoregulatory role under conditions characterized by a modest drop in arterial plasma glucose (65 mg/dl). The results are consistent with a glucose-sensing role for the carotid bodies. In response to a moderate fall in glucose, CBR had reduced glucagon and cortisol levels and a diminished R a response. The interpretation of these studies however is complex. These studies also demonstrated the interesting and potentially important finding that carotid body resection and denervation of the carotid sinus region reduces basal glucagon. It is conceivable that this, in itself, may impair the ability of the liver to respond to the metabolic stress caused by mild hypoglycemia.
Evidence that the carotid bodies are sensitive to glucose is provided by data showing that intracarotid infusions of glucose in vivo in dogs, cats, and rats cause a decrease in carotid chemosensory discharges, whereas mannitol does not (6) . It has also been reported that perfusion of the rat carotid bifurcation with hyperglycemic blood from a donor animal decreases blood glucose retention in the brain, whereas perfusion of the same area with hypoglycemic blood has the opposite effect (7). Moreover, incubation of the cat carotid body with 2-deoxyglucose, creating a model of glucopenia, causes an increase in electrical activity of the carotid nerve (8) . It has also been shown that stimulation of the carotid bodies in vivo using NaCN in the anesthetized rat (8) or a reduction in PaO 2 in the conscious dog (9) creates hormonal and metabolic responses similar to those that occur with hypoglycemia and stress. Hypoxia has been shown to increase cortisol secretion, an effect that is alleviated by carotid body denervation (10) . Carotid bodies have unique physiological characteristics that are consistent with a role for detecting changes in arterial blood glucose in the whole body. The carotid bodies have the highest blood flow and metabolic rate per gram of tissue in the body and are extensively innervated (11) . These physiological characteristics provide a basis for highly sensitive detection of arterial glucose and other controlled variables (e.g., pH and PO 2 ). The high rate of blood flow insures that all the cells that comprise the carotid bodies are well perfused with blood containing concentrations that are equivalent or close to arterial levels (i.e., arteriovenous differences are reduced at high blood flow rates). The high metabolic rate of the carotid bodies increases the likelihood that any deficit in provision of a metabolic substrate (i.e., glucose and O 2 ) will be detected in this tissue first.
The possibility that the carotid bodies are a physiological sensor of blood glucose adds to an already complex scheme. Sites in the brain (1, 19) , liver (4, 20) , portal vein (2,3) and pancreas (5) have all been implicated in blood glucose sensing. Despite intensive investigation, the physiological role of these glucose-sensitive regions is highly controversial. Several studies were done to test the role of the brain in directing the counterregulation to insulin-induced hypoglycemia by infusing glucose into the carotid and/or vertebral arteries (1, 19, 21, 22) . Cane et al. (21) concluded that near-maintenance of brain euglycemia (based on jugular vein glucose) with a bilateral carotid artery glucose infusion was ineffective in alleviating the counterregulatory response to systemic insulin-induced hypoglycemia. In contrast to this finding, Frizzell et al. (19) showed that bilateral perfusion of the carotid arteries with glucose at a rate calculated to keep the blood in these vessels euglycemic attenuated the glucagon, cortisol, and endogenous glucose production responses to insulin-induced hypoglycemia by ~40%. Combined bilateral vertebral and carotid artery glucose infusions led to an obliteration of the total responses. These studies are relevant to the present experiments in that the region perfused by the carotid arteries in these previous studies included the carotid sinus region. In contrast to the present study in which the systemic hypoglycemia was only moderate, these previous studies were done using deeper hypoglycemia (~50 mg/dl). The work of Frizzell et al. (19) suggests that glucose sensing in tissues perfused by the cerebrovasculature occurs at multiple sites because selective glucose perfusion into either the carotid or vertebrobasilar region can attenuate responses to hypoglycemia. It is possible that the recruitment of sensing regions depends on the degree of hypoglycemia so that carotid sinus receptors are recruited with smaller decrements in blood glucose than in other regions. This possibility is consistent with the remarkable access of the carotid body/sinus afferents to arterial blood.
Several studies have evaluated the role of the brain, specifically the ventromedial hypothalamus (VMH), in the response to hypoglycemia by lesioning sites in the VMH (23) , supplying glucose to the VMH during systemic hypoglycemia (24) , and administering 2-deoxyglucose to the VMH (25, 26) . These results show that a VMH center plays an important role in the response to hypoglycemia. The VMH is clearly sensitive to glucose and may be an integration hub for signals from other sites. The relative importance of the VMH in sensing blood glucose in relation to other putative sensing sites is difficult to ascertain. There is also evidence from the work of Donovan and colleagues that liver (4, 20, 27) or, more specifically, portal vein (2,3) glucose sensors may partially govern the sympathoadrenal response to hypoglycemia. Considering the importance of maintaining euglycemia, it is not unreasonable to believe that glucose sensors exist at multiple sites to create redundancy in protection against even mild hypoglycemia.
Glucagon is known to play a role in maintenance of basal R a (28) and in counteracting hypoglycemia (29) . CBR was associated with a reduction in arterial glucagon in the basal state (10 pg/ml) and during mild insulin-induced hypoglycemia (30 pg/ml). Interestingly, basal glucose production in CBR was similar to that observed in Sham, suggesting that basal glucagon is not critical for maintenance of basal glucose production or that there is some form of compensation for the chronic reduction in arterial glucagon. Because arterial plasma glucose and insulin were the same in CBR and Sham, any compensation would seem to involve mechanisms that are independent of these 2 regulators. In contrast, the R a response to mild insulin-induced hypoglycemia was completely eliminated by CBR. One interesting result was that the NHGO did not show the same profound differences between CBR and Sham as R a . Although NHGO tended to be lower in CBR, differences were not significant. One could speculate that there is a concomitant reduction in hepatic glucose utilization in CBR that counterbalances the reduction in R a . Perhaps it is more likely, however, that the added technical difficulties with the measurement of balances (precise measurement of blood flow and small arteriovenous differences) prevented the detection of significant differences.
The marked reduction in the response of R a to hypoglycemia in CBR, on the other hand, is more than one would predict from an impairment in glucagon levels alone (29) . Arterial cortisol was also reduced and may have contributed to the reduced R a during hypoglycemia, perhaps because of its ability to acutely stimulate gluconeogenesis (30) . Other effects of cortisol are primarily thought to be long-term, requiring many hours (31) . Arterial epinephrine was ~50% lower during hypoglycemia in CBR compared with Sham. Differences were not significant. It is possible that the compilation of small reductions in different counterregulatory responses, even those like epinephrine where significant differences could not be detected, may sum to cause the much larger deficit in R a . Hepatic sympathetic drive was not determined in these studies, and therefore, its contribution to the impaired counterregulatory response cannot be assessed. One cannot rule out Data are means ± SE. n = 6 and 6 in Sham and CBR, respectively. *Significant difference from Sham (P < 0.05).
that a deficit in other counterregulatory factors not measured contributes to the impaired R a response (e.g., growth hormone and undefined regulator). CBR and Sham were also studied during euglycemic clamps to control for the possibility that carotid body resection is not affecting the response to hypoglycemia, but instead, is affecting the response to moderate hyperinsulinemia. In addition to the lower R a , a greater R d contributed to the added glucose requirement during hypoglycemic clamp studies in CBR. This was an effect of CBR that was evident in the euglycemic studies as well and therefore was unrelated to hypoglycemic counterregulation. A possible mechanism for the elevation in R d in CBR may be the reduced PaO 2 . We have previously shown that a marked reduction in arterial PO 2 to 27 mmHg caused a modest increase in R d at basal insulin levels (32) . Unless glucose utilization is more sensitive to a decrement in PO 2 under hyperinsulinemic conditions, it is unlikely that the small PaO 2 seen in the present studies was a factor. It is well known that another metabolic stress, physical exercise, causes a dramatic increase in insulin sensitivity (33) . There were no other detectable glucoregulatory effects of carotid body resection during euglycemic clamps. As discussed earlier, basal arterial glucagon was significantly lower in CBR. Glucagon levels converged during the euglycemic clamp so that levels in CBR and Sham were similar by the end of the clamp. Cortisol was essentially the same in Sham and CBR, except for the initial sampling interval of the clamp where levels were elevated in Sham. As discussed in RESULTS, this appears to be an atypical response in Sham rather than an effect of carotid body resection. These data suggest that except for the stimulation of R d , the effects of CBR are specific to the moderate decrement in blood glucose.
The carotid bodies are difficult to visualize in the dog. Therefore, we took the precaution of denervating the region immediately surrounding the tissue where the carotid bodies were presumed to be located as added insurance that no signal from the carotid bodies was transmitted to the central nervous system. The absence of a pulmonary response to intravenous NaCN injection in CBR confirmed that the procedure was successful. A consequence of surgical procedures in CBR is the likelihood that all or some of the innervation to baroreceptors in the carotid sinus as well as the carotid bodies were removed. Arterial systolic and diastolic blood pressures were similar in CBR and Sham not only in the basal state (Table 1) but throughout the clamp periods, suggesting that compensation for the removal of any baroreceptors was effective. It is unlikely that there was any damage to the vagii during the carotid body resection because the vagii and the carotid sinus are readily distinct visually during surgery and are separated by ~2 cm. In addition, there was no detectable evidence that vagal function was impaired (normal gastrointestinal function and normal heart rate). We cannot rule out however that the pharyngeal and auricular branches of the vagus are damaged by the carotid body resection because these nerves are small and near the dissected region. These nerves innervate the outer ear canal, the caudal pharyngeal muscles, and the cranial esophagus and are unlikely to be directly involved in glucose sensing. It is also important to note that the effect of carotid body resection was evident even though the chemical-sensing cells at the aortic arch (the aortic bodies) were left intact. One can therefore conclude that either the aortic bodies are not important in this response or the role of arterial receptors is underestimated. As expected, PaO 2 and PCO 2 were reduced to 80 mmHg and increased to 42 mmHg, respectively, in CBR. This result is added confirmation that the carotid bodies were no longer effective (34) . CBR had a similar arterial pH to Sham, indicating that renal compensation for the greater retention of CO 2 was complete. It is possible that one or both of these changes in blood gas concentration affected glucoregulation by some undefined mechanism. In a previous study, we examined the effects of decreasing PaO 2 on liver and muscle glucose metabolism and whole-body glucose fluxes in the dog (9) . There was no effect on glucose metabolism of reducing PaO 2 until it was <60 mmHg. As noted above, however, it is possible that effects of decreased PaO 2 may be augmented during hyperinsulinemia.
The glucoregulatory role of the carotid bodies may have clinical implications. There is evidence that carotid body function is impaired in diabetic patients. This is suggested by data that show the ventilatory response to hypoxia, which is mediated by the carotid bodies, is diminished in diabetic patients (35) (36) (37) (38) . Impaired carotid body function may result from the increased carotid artery wall intima-media thickness that often accompanies glucose-intolerant or insulin-resistant states (39) (40) (41) (42) (43) (44) . Whether carotid body dysfunction plays a role in the pathogenesis of diabetes needs to be studied in more detail.
This study was designed to characterize the role of the carotid bodies in the basal state and in mediating the response to insulin-induced hypoglycemia in a conscious dog model. The results of the present study illustrate that CBR is associated with 1) lower basal arterial glucagon and reduced glucagon and cortisol levels during insulin-induced hypoglycemia, 2) a marked decrease in the R a response to hypoglycemia, and 3) an increase in insulin-stimulated R d that is independent of blood glucose level. In conclusion, these findings provide evidence that carotid bodies, or nearby receptors, play a role in the physiology of glucoregulation and, potentially, in the pathology of diabetes.
